The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

AdChoices
 

Biomarin Pharmaceutical Inc

Nasdaq: BMRN
Last

(U.S.) $88.62

Today's change-4.92 -5.26%
Updated October 18 4:00 PM EDT. Delayed by at least 15 minutes.
 

Biomarin Pharmaceutical Inc

Nasdaq: BMRN
Last

(U.S.) $88.62

Today's change-4.92 -5.26%
Updated October 18 4:00 PM EDT. Delayed by at least 15 minutes.

Biomarin Pharmaceutical Inc crosses below 200-day moving average

Biomarin Pharmaceutical Inc closed sharply lower Wednesday, dropping (U.S.)$4.92 or 5.26% to (U.S.)$88.62 and crossing below its 200-day moving average. Shares have lost 6.65% over the last five days, but have gained 6.98% over the last year to date. This security has underperformed the S&P 500 by 15.94% during the last year.

Key company metrics

  • Open(U.S.) $93.40
  • Previous close(U.S.) $93.54
  • High(U.S.) $94.76
  • Low(U.S.) $86.90
  • Bid / Ask(U.S.) $89.05 / (U.S.) $89.45
  • YTD % change+6.98%
  • Volume3,819,499
  • Average volume (10-day)942,591
  • Average volume (1-month)1,218,704
  • Average volume (3-month)1,323,362
  • 52-week range(U.S.) $78.42 to (U.S.) $100.51
  • Beta1.80
  • Trailing P/ENegative, not meaningful
  • P/E 1 year forwardNegative, not meaningful
  • Forward PEGNegative, not meaningful
  • Indicated annual dividend--
  • Dividend yield0.00%
  • Trailing EPS(U.S.) -$1.02
Updated October 18 4:00 PM EDT. Delayed by at least 15 minutes.
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q2/2017Q1/2017Q4/2016Q3/2016
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedJun 30, 201706/30/2017Mar 31, 201703/31/2017Dec 31, 201612/31/2016Sep 30, 201609/30/2016
Revenue317304300280
Total other revenue--------
Total revenue317304300280
Gross profit261254236229
Total cost of revenue56506451
Total operating expense356324390340
Selling / general / administrative150119153120
Research & development143145175161
Depreciation / amortization8888
Interest expense (income), net operating--------
Unusual expense (income)0--00
Other operating expenses, total6102
Operating income-39-20-90-60
Interest income (expense), net non-operating-10-10-10-10
Gain (loss) on sale of assets--------
Other--------
Income before tax-46-24-92-67
Income after tax-37-16-79-43
Income tax, total-9-8-13-24
Net income-37-16-79-43
Total adjustments to net income--------
Net income before extra. items-37-16-79-43
Minority interest--------
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items-37-16-79-43
Inc. avail. to common incl. extra. items-37-16-79-43
Diluted net income-37-16-79-43
Dilution adjustment--------
Diluted weighted average shares174173172168
Diluted EPS excluding extraordinary itemsvalue per share-0.21-0.09-0.46-0.26
Dividends per sharevalue per share0.000.00--0.00
Diluted normalized EPSvalue per share-0.21-0.09-0.46-0.26